Joint Statement on Horizon Europe Cancer Mission

Every European citizen is affected by cancer, either directly or indirectly. In that perspective The European Commission wrote the interim report ‘Conquering Cancer: Mission Possible’, aiming to deliver concrete solutions on this matter. The Board for the Mission on Cancer is proposing an ambitious goal: “By 2030, more than 3 million lives saved, living longer and better”.

The draft report presents 13 recommendations for bold actions to understand cancer, its risk factors and impact. The Cancer Mission Board also recognises the role of European Life Science Research Infrastructures (LS RI) to support some of its preliminary recommendations. Already providing multidisciplinary research communities from any European country with efficient access to academic expertise, facilities and research data, our research infrastructures are uniquely placed to help address cancer research challenges.

Joint statement on the Cancer Mission

In this context BBMRI, EATRIS, ECRIN and ELIXIR can contribute to the success of the Horizon Europe Mission on Cancer. Together, a more in-depth statement on the draft report on the Cancer Mission has been published. The full statement explains more in detail what we can do for the mission and for the European cancer research community.

We look forward to continuing our dialogue with the Cancer Mission Board and all other relevant stakeholders to set the Cancer Mission for success and to save the lives of European citizens.

About Horizon Europe Cancer Mission

The Cancer Mission Board’s interim report, Conquering Cancer: Mission Possible, with its 13 recommendations, represent a significant step towards an ambitious Mission strategy. The recommendations address the whole cancer continuum and offer a comprehensive plan that will require the commitment of all relevant stakeholders at national and EU level, including the one from European research infrastructures. The Cancer Mission has been launched under the Horizon Europe Framework Programme for Research and Innovation (2021-2027).